Literature DB >> 17986680

Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs.

Elaine H Morrato1, Anne M Libby, Heather D Orton, Frank V Degruy, David A Brent, Richard Allen, Robert J Valuck.   

Abstract

OBJECTIVE: The Food and Drug Administration (FDA) issued a public health advisory in October 2003 on the risk of suicide in pediatric patients taking antidepressants and advised maintaining "close supervision" of such patients. In this study, the authors compared trends in the frequency of provider contacts for patients with depression before and after the advisory was issued.
METHOD: Retrospective cohorts of children (N=27,370) and adults (N=193,151) with new episodes of depression treated with antidepressants were created from a national claims database of managed care plans (1998-2005). Two standards were used in measuring patient monitoring: the Health Plan Employer Data and Information Set (HEDIS) quality-of-care criterion calling for three contacts in 3 months and the FDA-recommended contact schedule totaling seven visits in 3 months. Time-series models compared postadvisory trends to the expected trend based on preadvisory measures.
RESULTS: Less than 5% of all patients met FDA contact recommendations before the advisory, and the rate did not change after the advisory. A greater proportion of patients met the HEDIS contact criterion before the advisory (60% for children and 40% for adults), and the rate did not change after the advisory. A greater proportion of pediatric patients seen by a psychiatrist (80%) met the HEDIS criterion than those seen by a pediatrician (60%) or a non-pediatrician primary care physician (54%), and than adults seen by a psychiatrist (65%) or a primary care physician (37%). The proportions of pediatric patients who met the FDA recommendations did not differ by specialty.
CONCLUSIONS: Contrary to expectations, the frequency of visits by patients with new episodes of depression treated with antidepressants did not increase after the October 2003 FDA advisory was issued.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17986680     DOI: 10.1176/appi.ajp.2007.07010205

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  33 in total

Review 1.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome.

Authors:  Bret R Rutherford; Jane Tandler; Patrick J Brown; Joel R Sneed; Steven P Roose
Journal:  Am J Geriatr Psychiatry       Date:  2013-11-05       Impact factor: 4.105

3.  Does direct-to-consumer advertising of antidepressants lead to a net social benefit?

Authors:  Jon Jureidini; Barbara Mintzes; Melissa Raven
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Antidepressants and suicide in adolescents and adults: a public health experiment with unintended consequences?

Authors:  Jack Alan McCain
Journal:  P T       Date:  2009-07

Review 5.  Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

Authors:  Stacie B Dusetzina; Ashley S Higashi; E Ray Dorsey; Rena Conti; Haiden A Huskamp; Shu Zhu; Craig F Garfield; G Caleb Alexander
Journal:  Med Care       Date:  2012-06       Impact factor: 2.983

Review 6.  Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.

Authors:  Henry J Riordan; Paola Antonini; Michael F Murphy
Journal:  Am Health Drug Benefits       Date:  2011-09

7.  The multidisciplinary depression guideline for children and adolescents: an implementation study.

Authors:  Marleen L M Hermens; Matthijs Oud; Henny Sinnema; Maaike H Nauta; Yvonne Stikkelbroek; Daniëlle van Duin; Michel Wensing
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-01-15       Impact factor: 4.785

8.  News coverage of FDA warnings on pediatric antidepressant use and suicidality.

Authors:  Colleen L Barry; Susan H Busch
Journal:  Pediatrics       Date:  2009-12-07       Impact factor: 7.124

Review 9.  A model of placebo response in antidepressant clinical trials.

Authors:  Bret R Rutherford; Steven P Roose
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

10.  Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

Authors:  Elaine H Morrato; John W Newcomer; Siddhesh Kamat; Onur Baser; James Harnett; Brian Cuffel
Journal:  Diabetes Care       Date:  2009-02-24       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.